GlassScriptPhysician profile
Algie M Labrasca
NPI 1194924084
$943.35
in general payments reported to CMS, 2019-2025
13 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.61 · 2020: $28.27 · 2021: $79.74 · 2022: $31.37 · 2023: $171 · 2024: $398 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $301.44 | 2020-2025 | |
| Abbvie INC. | $170.97 | 2024 | |
| Mentor Worldwide LLC | $116.94 | 2021-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Ethicon US, LLC | $66.46 | 2021-2025 | Monocryl, Stratafix |
| Merz North America, INC. | $61.61 | 2019 | |
| Revance Therapeutics, INC. | $52.76 | 2025 | Daxxify |
| Next Science LLC | $50.00 | 2023 | Surgx, Xperience, Blastx |
| Allergan, INC. | $35.84 | 2020-2022 | |
| Organogenesis INC. | $26.62 | 2024 | |
| Kci USA, INC. | $20.33 | 2021 | |
| Acelrx Pharmaceuticals, INC. | $15.62 | 2021 | |
| Bard Peripheral Vascular, INC. | $12.99 | 2021 | |
| Bioventus LLC | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Algie Labrasca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.